VCR-045

VCR-045 is a bispecific antibody drug candidate developed by Vicero Bio. It is designed to simultaneously target Programmed cell death protein 1 (PD-1) and Vascular endothelial growth factor receptor (VEGFR). The drug acts as both a PD-1 inhibitor and a VEGFR antagonist, aiming to modulate immune responses and inhibit angiogenesis, respectively. As of the latest update, VCR-045 remains in the discovery phase of development with no active clinical indications reported. Its mechanism suggests potential use in immuno-oncology, particularly for solid tumors where checkpoint inhibition and antiangiogenic strategies are relevant[1][8].